Mythic Therapeutics, Inc. (United States)

Homepage: mythictx.com

Alternate names: Mythic Therapeutics, Mythic Therapeutics, Inc.

ROR: 02f6prq47

OpenAlex ID: I4405267374

Biparatopic antibodies: therapeutic applications and prospects

2024 · David L. Niquille, Kyle M. Fitzgerald, et al. · mAbs · 60

The evolution of bispecific antibodies

2022 · Nimish Gera · Expert Opinion on Biological Therapy · 34

MYTX-011: A pH-Dependent Anti–c-MET Antibody–Drug Conjugate Designed for Enhanced Payload Delivery to c-MET–Expressing Tumor Cells

2024 · Nimish Gera, Kyle M. Fitzgerald, et al. · Molecular Cancer Therapeutics · 16

S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models

2024 · Lauren R. Begg, Adrienne M. Orriols, et al. · Communications Medicine · 11

Yeast Display Guided Selection of pH-Dependent Binders

2022 · Jenna N. Meanor, Albert J. Keung, et al. · Methods in molecular biology · 6

Abstract 5000: MYTX-011: A novel cMET-targeting antibody drug conjugate (ADC) engineered to increase on-target uptake in and efficacy against cMET expressing tumors

2023 · Nimish Gera, Kyle Fitzgerald, et al. · Cancer Research · 5

MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study.

2025 · Rebecca Heist, Elaine Shum, et al. · Journal of Clinical Oncology · 4

MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study.

2024 · Melissa Lynne Johnson, Timothy F. Burns, et al. · Journal of Clinical Oncology · 4

Phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate (ADC) MYTX-011 in subjects with non-small cell lung cancer.

2023 · Alexander I. Spira, Melissa Lynne Johnson, et al. · Journal of Clinical Oncology · 2

1946P MYTX-011, a pH-dependent cMET-targeting ADC, demonstrates anti-tumor activity across a broad spectrum of cMET expressing NSCLC

2025 · E. Shum, V. Gambardella, et al. · Annals of Oncology

Abstract 2960: MYTX-011: A pH-dependent anti-cMET ADC exhibits potent activity in multiple epithelial tumor models with clinically actionable mutations and varying levels of cMET expression

2025 · Deepak Kanojia, Federico Colombo, et al. · Cancer Research

Abstract 1907: MYTX-011: A pH-dependent anti-cMET ADC with increased payload delivery in vivo and potent activity against cMET-expressing tumors of various epithelial origins

2024 · Deepak Kanojia, William Comb, et al. · Cancer Research

Abstract B124: MYTX-011 is a highly internalized ADC with anti-tumor activity across a spectrum of NSCLC preclinical models with various levels of cMET expression

2023 · William C Comb, Deepak Kanojia, et al. · Molecular Cancer Therapeutics

Works count: 13

Citation count: 575